We are developing a new software that will do magic of predicting the behavior of penny stocks. Previously we worked on developing cool apps that did magic through machine learning algorithms. Check out what this machine learning magic was capable.
However, we decided to put our efforts and Artificial Intelligence Magic into developing a smart engine that will be able not only to analyze the data, but provide simulations of the future financial market behavior.
Last week we ran a few simulations with our algorithms, did research and analysis and picked up MATN stock that will perform well in the coming weeks.
- Mateon Therapeutics, Inc. is a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, with its lead program in acute myeloid leukemia and myelodysplastic syndromes. Mateon is committed to leveraging its product development expertise and intellectual property to bring improved and medically necessary new therapies to cancer patients worldwide.
- On September 30, 2017, Mateon had cash and short-term investments of $1.9 million.
- Mateon Therapeutics is in Phase 1b/2 study and development of a revolutionary drug OXi4503 (NCT02576301) in patients with relapsed and refractory myelogenous leukemia (AML) or myelodysplastic syndrome (MDS), please visit clinicaltrials.gov
Based on these Facts and Artificial Intelligence algorithms, we are confident that MATN stock will growth more than 200% in the coming weeks.